Abstract
Introduction
The transplant immunosuppressant market has seen considerable growth in recent
years, but this is expected to slow down. Two factors combine to cause a
decline in the market from 2011, the limited availability of donor organs and
patent expiries of several key products. Neither the shift to once-daily
formulations nor the launch of novel biologic therapies will prevent the
contraction.
Scope of this research
- Forecasts for immunosuppressants used in solid organ transplantation and
significant pipeline drugs (to 2017 in report and to 2018 in excel tool)
- Market overview by geographical area, including a rest of the world
snapshot and a case study on the Canadian transplant market
- Future market outlook for individual products taking into account key
market events, in particular patent expiry and competitor launch dates
- An overview of key companies active in the transplant market and their
strategies
Research and analysis highlights
Datamonitor expects immunosuppressant sales in the seven major markets to grow
to about $4.7 billion annually by 2011, after which the market is forecast to
slowly decline to $4.4 billion by 2017 due to key products' patent expiries.
The immunosuppressant market overall will be held back by the limited
availability of organs.
Bristol-Myers Squibb' s once-monthly monoclonal belatacept is expected to be
the top-selling single brand in the seven major markets in 2017. However, the
combined sales of Astellas' s tacrolimus franchise (Prograf and once-daily
Advagraf) will dominate the immunosuppressant market over the next ten years.
The toxicity associated with calcineurin inhibitors will lead to more emphasis
on immunosuppressive regimens that permit reduction or avoidance of products
from this class while maintaining adequate immunosuppression and graft
survival. This leads to a fertile environment for novel immunomodulatory
approaches.
Key reasons to purchase this research
- Identify key opportunities and threats that will impact the use and uptake
of new and existing products
- Quantify the future size and scope of the transplant immunosuppressant
market and predict the performance of key compounds
- Understand and capitalize on clinical unmet needs in the market through
both lifecycle management of marketed drugs and new product development
| 
View Cart
